Baseline characteristics of the total cohort
ISTH-BAT bleeding score . | Adults (n = 209) . | Children (n = 116) . | ||
---|---|---|---|---|
Abnormal n = 145 . | Normal n = 64 . | Abnormal n = 75 . | Normal n = 41 . | |
Country | ||||
United States/Canada | 35 (24.1) | 22 (35.9) | 75 (100) | 41 (100) |
Ireland | 110 (75.9) | 41 (64.1) | 0 | 0 |
Sex | ||||
Female | 135 (93.1) | 49 (76.6) | 51 (68.0) | 22 (53.7) |
Male | 10 (6.9) | 15 (23.4%) | 24 (32.0) | 19 (46.3) |
Blood group | ||||
O | 115 (92.0) | 47 (88.7) | 33 (89.2) | 11 (84.6) |
Non-O | 10 (9.0) | 6 (11.3) | 4 (10.8) | 2 (15.4) |
Age, y | 38.4 ± 13.6∗ | 33.0 ± 12.2∗ | 11.6 ± 4.6† | 6.7 ± 41† |
ISTH-BAT | 10.3 ± 4.6† | 2.6 ± 1.7† | 5.8 ± 2.6† | 1.1 ± 0.9† |
VWF:Ag | 57.3 ± 15.4† | 50.5 ± 10.7† | 42.7 ± 7.7∗ | 46.4 ± 7.0∗ |
VWF:RCo | 48.3 ± 13.5∗ | 43.3 ± 8.5∗ | 40.4 ± 7.9 | 42.7 ± 8.2 |
ISTH-BAT bleeding score . | Adults (n = 209) . | Children (n = 116) . | ||
---|---|---|---|---|
Abnormal n = 145 . | Normal n = 64 . | Abnormal n = 75 . | Normal n = 41 . | |
Country | ||||
United States/Canada | 35 (24.1) | 22 (35.9) | 75 (100) | 41 (100) |
Ireland | 110 (75.9) | 41 (64.1) | 0 | 0 |
Sex | ||||
Female | 135 (93.1) | 49 (76.6) | 51 (68.0) | 22 (53.7) |
Male | 10 (6.9) | 15 (23.4%) | 24 (32.0) | 19 (46.3) |
Blood group | ||||
O | 115 (92.0) | 47 (88.7) | 33 (89.2) | 11 (84.6) |
Non-O | 10 (9.0) | 6 (11.3) | 4 (10.8) | 2 (15.4) |
Age, y | 38.4 ± 13.6∗ | 33.0 ± 12.2∗ | 11.6 ± 4.6† | 6.7 ± 41† |
ISTH-BAT | 10.3 ± 4.6† | 2.6 ± 1.7† | 5.8 ± 2.6† | 1.1 ± 0.9† |
VWF:Ag | 57.3 ± 15.4† | 50.5 ± 10.7† | 42.7 ± 7.7∗ | 46.4 ± 7.0∗ |
VWF:RCo | 48.3 ± 13.5∗ | 43.3 ± 8.5∗ | 40.4 ± 7.9 | 42.7 ± 8.2 |
Data are presented as n (%) or mean ± standard deviation. All P values are outcomes of independent t tests between individuals with abnormal vs normal ISTH-BAT bleeding scores. Normal ISTH-BAT reference ranges are 0 to 2 for children, 0 to 5 for adult females, and 0 to 3 for adult males.
VWF:RCo, VWF ristocetin cofactor activity.
P < 0.01.
P < 0.001.